Status:
COMPLETED
A Crossover Study Assessing the Pharmacokinetics, Pharmacodynamics, and Safety of Recombinant Human Insulin
Lead Sponsor:
Baxter Healthcare Corporation
Conditions:
Healthy
Eligibility:
MALE
18-40 years
Phase:
PHASE1
Brief Summary
The purpose of this study is to assess the pharmacokinetics, pharmacodynamics, and safety of recombinant human insulin. The study will consist of 2 phases.
Eligibility Criteria
Inclusion
- Healthy Male Subjects
- Age between 18 and 40 years of age
Exclusion
- History of Diabetes
- Subjects with clinically significant active disease
- Known allergy to insulin
Key Trial Info
Start Date :
Trial Type :
INTERVENTIONAL
End Date :
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00358553
Last Update
March 13 2007
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Profil
Neuss, Germany